MidCap Financial Investment (NasdaqGS:MFIC) Q3 2025 Earnings Call November 07, 2025 08:30 AM ET Company ParticipantsElizabeth Besen - Investor Relations ManagerKenneth Seifert - CFOTed McNulty - PresidentTanner Powell - CEOConference Call ParticipantsPaul Johnson - VP and Equity Research AnalystArren Cyganovich - Equity Research AnalystMelissa Wedel - AnalystKenneth Lee - VP, Senior Equity AnalystOperatorThank you for your continued patience. Your meeting will begin shortly. If you need assistance at any ti ...

MidCap Financial Investment (NasdaqGS:MFIC) Q3 2025 Earnings Call November 07, 2025 08:30 AM ET Speaker0Thank you for your continued patience. Your meeting will begin shortly. If you need assistance at any time, please press star zero, and a member of our team will be happy to help you. Please stand by. Your meeting is about to begin. Good morning and welcome to the earnings conference call for the period ended September 30, 2025, for MidCap Financial Investment Corporation. At this time, all participants h ...

Welcome to CBC. com. I'm Frank Colin, anchor of Worldwide Exchange.We are taking a look at the ETF market, which as of today has $1.13% trillion in net inflows, just a tick below the record set last year. And we are on pace for another record year this year. With that, I want to bring in my guest for today.It's Anaket Ulfra, head of their ETF business. Anakette, thanks for joining us. >> Thanks for having me, Frank.Um, first off, let me talk to you about the fact that ETF inflows are going to hit a record f ...

Codexis (NasdaqGS:CDXS) Q3 2025 Earnings Call November 06, 2025 04:30 PM ET Speaker1Greetings and welcome to the Codexis third quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow a formal presentation. If anyone should require operator assistance during this conference, please press star zero on your telephone keypad. Please note that this conference is being recorded. I will now turn the conference over to your host, Geo ...

Announces signing of $37.8m Supply Assurance Agreement with Merck Organizational changes streamline company and reduce operational expenses Cash runway extended through 2027 REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced financial results for the third quarter ended September 30, 2025. The company also provided a business update that includes ...

President Trump put pharmaceutical CEOs on notice, demanding they lower drug prices or he promised to get involved.  He penned a letter to 17 CEOs, in July, outlining what he wants from the pharma industry to cut expenses for consumers.In many cases, Americans are paying higher prices for drugs that treat common conditions, while customers in foreign countries pay less.  FOX Business takes a look at the top five most expensive drugs by sales in the U.S. and what they are likely to cost consumers out of pock ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q New Jersey 22-1918501 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File No. 1-6571 Merck & Co., Inc. (Exact name of registrant as specified in its charter) (State or other jurisdicti ...

Corporate Presentation November 4, 2025 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements related to the potential benefits of Vaxcyte's carrier-sparing platform and vaccine candidates, including breadth of coverage and the ability to deliver potentially better immune responses, a potentially best-in-class pneumococcal conjugate vaccine (PCV) ...

Key Points Recursion Pharmaceuticals currently has the industry's largest AI supercomputer. It also has partnerships with major drugmakers, but these have yet to yield major wins. Recursion'a lack of clinical success makes the stock very risky for investors now. 10 stocks we like better than Recursion Pharmaceuticals › Recursion Pharmaceuticals (NASDAQ: RXRX) is a relatively small player in the biotech industry. The same is true in artificial intelligence (AI), a market where it is barely on the m ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Foundation Launches $22 Million Initiative to Improve Cardiovascular Care in the U.S. ...